Depixus has entered a collaboration with Daiichi Sankyo to use their novel MAGNA technology to accelerate Daiichi’s RNA-targeted drug discovery program.

Based on magnetic force spectroscopy, MAGNA is a technology that enables high-throughput analysis of dynamic biomolecular interactions in real time with single-molecule resolution. For RNA these insights reveal how small molecules and proteins bind to three-dimensional RNA structures and provide valuable information about binding kinetics and mode of action.

Daiichi Sankyo will use MAGNA to explore the interactions of lead molecules with a number of undisclosed RNA targets. The data will inform hit-to-lead selection and lead optimization for the company’s RNA-targeted therapeutics pipeline as they move towards the clinic.

Gordon Hamilton, CEO of Depixus, said, “The world of RNA-targeted therapeutics has huge potential, yet is largely unexplored. We are excited to partner with Daiichi Sankyo to put MAGNA to work in pursuit of our shared vision of creating novel medicines to treat diseases with high unmet need.”

Depixus is currently discussing collaborations with other global pharmaceutical and biotech partners to explore challenging novel targets and accelerate the next generation of life-changing therapeutics. The company is also aiming for the commercial launch of its MAGNA One instrument in 2024.